Partner Content Partner Content Neurostimulation Devices Market will achieve 15% CAGR up to ... Neurostimulation Devices Market to reach $19bn by 2025
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.